HEALTHMEDPAGE TODAY
Evolution of Perioperative Immunotherapy in Resectable Esophageal Cancer
The article discusses the emergence and ongoing promise of immunotherapy for resectable esophageal cancer, a disease historically associated with poor prognosis. It highlights that immunotherapy has provided hope to patients and clinicians, with recent developments suggesting sustained or improved outcomes.
Mentioned
Related Signal
Adjacent reporting
- A Deadly Cancer Is Seeing Real Progress
- New Strategies and Platforms for Gastroesophageal Cancer
- SMALL CAP IDEA: Poolbeg Pharma and the oral drug that could unlock cancer immunotherapy's biggest problem
- STAT+: A turning point for pancreatic cancer patients
- Delivering an immune therapy into tumours instead of intravenously reduces adverse effects
- Landmark cancer trial shows success against ‘undruggable’ cancer — raising hopes for future treatments